Latest Pharmacy Operations News

Green Cross Health CEO Rachael Newfield will step down in January 2027 following the sale of the Medical division, paving the way for a new pharmacy-centric leadership role.

LTR Pharma has locked in a comprehensive commercial agreement with Strive Pharmacy, cementing its manufacturing and fulfilment infrastructure for the upcoming US launch of ROXUS®.

Green Cross Health plans to sell its Medical division, The Doctors, for NZ$270 million to Tend Health, refocusing on its pharmacy business. Completion hinges on shareholder approval expected by July 2026.

Green Cross Health lifted net profit by 28% to NZD 20.4 million in FY26, driven by stronger medical funding and pharmacy revenue growth, while preparing to launch a new Primary Health Organisation.

Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.

Green Cross Health (NZX: GXH) has acknowledged discussions with third parties about a possible sale of its Medical division but emphasised that no transaction is guaranteed. The company remains committed to updating shareholders as the situation develops.

Pharmx Technologies has entered a multi-year strategic alliance with Sigma Healthcare, becoming the preferred EDI provider for Sigma and Chemist Warehouse across Australia and New Zealand, while Sigma takes a significant equity stake.

Epsilon Healthcare has posted a record $2.891 million in receipts for the December 2025 quarter, nearly doubling year-on-year revenue and marking a significant turnaround with its recent ASX reinstatement.

Epsilon Healthcare has posted its highest-ever quarterly receipts of $2.919 million, reflecting a robust turnaround since exiting voluntary administration in mid-2024. The company’s strategic sale and leaseback deal has also enabled significant debt reduction, setting the stage for sustained growth.

Epsilon Healthcare reports a strong rebound with a 73% revenue increase in the June quarter, driven by contract manufacturing and new pharmacy operations. The company is emerging from restructuring with renewed financial strength and growth prospects.

The Supreme Court of New South Wales has approved the merger scheme between Washington H. Soul Pattinson and Brickworks, paving the way for a new ASX-listed entity, Topco. Shareholders will soon exchange their Soul Patts shares for Topco shares as trading transitions next week.

Pharmx Technologies has extended its pivotal National Diabetes Services Scheme agreement and expanded its supplier base, reinforcing its leadership in pharmacy digital infrastructure across Australia and New Zealand.